Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 5/20 | 0.38 |
| ▸ | THRA | P10827 | 4/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367730 | 0.79 | POLB (0.41) | POLBL3MBTL1THRBTHRAGSK3B | |
| SCHEMBL29185140 | 0.79 | GSK3B (0.50) | POLBL3MBTL1THRBTHRAGSK3B | |
| SCHEMBL4987918 | 0.77 | DAO (0.44) | GSK3BDAOKMT2AUSP2ALOX15 | |
| SCHEMBL9092222 | 0.73 | GSK3B (0.39) | POLBL3MBTL1GSK3BHPGDMAPT | |
| SCHEMBL10690798 | 0.72 | POLB (0.41) | POLBL3MBTL1THRBTHRADAO | |
| SCHEMBL365715 | 0.71 | AKR1B1 (0.38) | POLBL3MBTL1THRBGSK3BDAO | |
| SCHEMBL26924056 | 0.71 | MAPK1 (0.32) | HSD17B10MAPTGAAALDH1A1 | |
| SCHEMBL7351632 | 0.70 | HPGD (0.41) | POLBL3MBTL1DAOHPGDKMT2A | |
| SCHEMBL27836185 | 0.69 | GAA (0.49) | POLBDAOHPGDHSD17B10KMT2A | |
| SCHEMBL4572759 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | POLB 3974/4885L3MBTL1 1507/4885THRB 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.